Hyperbaric Oxygen Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (HBOT-ME/CFS)
Hyperbaric Oxygen Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - A Prospective, Randomized, Double-Blind, Sham-Controlled Study
調査の概要
詳細な説明
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Eli Kravchik, MD
- 電話番号:089779241
- メール:elikr@shamir.gov.il
研究連絡先のバックアップ
- 名前:Shai Efrati, Prof
- メール:efratishai@outlook.com
研究場所
-
-
-
Zrifin、イスラエル、70300
- 募集
- The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)
-
コンタクト:
- Shai Efrati, Prof
- 電話番号:972-8-9779393
- メール:efratishai@outlook.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Subject willing and able to read, understand and sign an informed consent
- Diagnosis of mild to moderate severity of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Patients diagnosed with CFS for more than 1 years
- Stable psychological and pharmacological treatment for more than three months prior to inclusion
Exclusion Criteria:
- Inability to attend scheduled clinic visits and/or comply with the study protocol
- Severe and very severe cases of ME/CFS
- History or diagnosis of, brain tumors, brain surgery, epilepsy, neurodegenerative diseases
- Active malignancy
- Substance use at baseline, except for prescribed cannabis if vaporized or taken PO as tincture
- Active smokers
- Chronic heart failure with ejection fraction of 30 or less
- Chest pathology incompatible with pressure changes (including active asthma or COPD)
- Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year)
- Pregnancy
- An inability to perform an awake brain MRI
- An inability to perform Neurotrax
- Participation in another medical study
- HBOT for any reason prior to study enrolment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Hyperbaric oxygen therapy
Hyperbaric Oxygen Therapy: 60 consecutive sessions, 5 sessions per week within a three months' period.
Each session includes breathing 100% oxygen by mask at 2 ATA for 90 minutes with 5-minute air breaks every 20 minutes.
|
60 consecutive sessions of breathing 100% oxygen by mask at 2 ATA for 90 minutes with 5-minute air breaks every 20 minutes, 5 sessions per week within a three months' period.
|
|
偽コンパレータ:Sham Hyperbaric oxygen therapy
SHAM therapy: 60 consecutive sessions, 5 sessions per week within a three months' period.
SHAM pressure will go up to 1.2 ATA during the first five minutes of the session (to simulate the pressure sensation in the ears), and then decrease during the next 5 minutes to 1.02 ATA for 90 minutes with 5-minute air breaks, every 20 minutes.
|
60 consecutive sessions of breathing 21% oxygen by mask at 1 ATA for 90 minutes with 5-minute air breaks every 20 minutes, 5 sessions per week within a three months' period.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cardiopulmonary exercise test (CPET)
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Physical performance evaluated by cardiopulmonary exercise test (CPET) on a bicycle or a treadmill. CPET will be used to determine the peak oxygen consumption (Peak VO2), first ventilatory threshold (VT1) and if possible, the second ventilatory threshold (VT2). The day after each CPET an FUNCAP55 questionnaire will be filled to assess the functional capacity. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
DePaul Post-Exertional Malaise Questionnaire (DPEMQ)
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
A self-report instrument assessing the frequency and severity of post-exertional malaise symptoms in individuals with ME/CFS. Total scores typically range from the minimum value (no symptoms) to the maximum value (most severe and frequent symptoms), with higher scores indicating worse post-exertional malaise. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Short Form-36 Health Survey (SF-36)
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
A self-reported measure of health-related quality of life across eight domains. Each SF-36 scale is transformed to a 0 to 100 score, where 0 represents the worst health status and 100 represents the best health status. Higher scores indicate better health-related quality of life. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Pittsburgh Sleep Quality Index (PSQI)
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
a self-report questionnaire that assesses sleep quality and disturbances over the previous month. The measure consists of 19 individual items, creating 7 components that produce one global score. The score ranges from 0 to 21, with higher scores indicating poorer sleep quality. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Brief Symptom Inventory-18 (BSI-18)
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
The BSI-18 will be used to evaluate psychological distress. An 18 item self-report questionnaire which generates a global stress index (GSI), and three subscales: depression, anxiety, and somatization. Each item is rated on a 5-point scale, with distress ratings ranging from 0 (not at all) to 4 (extremely). Higher scores indicate greater psychological distress. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
NeuroTrax
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
NeuroTrax (NeuroTrax Corp., Houston, TX) is a computerized neurocognitive battery of tests used to assess brain wellness across multiple cognitive domains, including memory, executive function, visual spatial perception, verbal function, attention, information processing speed, and motor skills
|
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Brain MRI
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Images will be acquired on MAGNETOM Vida 3T Scanner, T1-weighted images will be used for gray matter and hippocampal volumetric measurement. Statistical parametric mapping software SPM12, will be used for brain segmentation. Voxel-based morphometry (VBM) procedure to calculate the whole-brain volumes. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Brain EEG
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Resting-state and task-related brain EEG measures. EEG will be recorded using a high-density dry-electrode system (115 channels, EEG-Sense, Israel). Recordings will include eyes-open rest (3 minutes), eyes-closed rest (3 minutes), and 20 minutes of cognitive tasks (N-Back, Stroop, Flanker, and multiple-object tracking). EEG data will undergo standard preprocessing (filtering, line-noise and artifact removal, and down-sampling). Primary EEG outcomes will include spectral measures (peak frequency and relative power; alpha, beta, theta, and delta band power), power spectral distribution, and functional connectivity indices. Event-related potentials will be extracted for the cognitive tasks, including event-related synchronization and desynchronization (ERS/ERD), with averages computed across artifact-free trials. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Sleep EEG
時間枠:Baseline (3 consecutive nights within 2 weeks before treatment), post-treatment (3 consecutive nights within 21±7 days after last HBOT/Sham session), and at the end of the 3-month follow-up period (3 consecutive nights)
|
Physiological sleep EEG signals will be collected using a home wearable EEG headband (Muse S) paired with a mobile application. Multi-channel EEG will be recorded from frontal and temporal locations, together with inertial sensors to capture movement and head position. Primary sleep EEG outcomes will include validated sleep-wake classification and sleep staging metrics (percent time in light, deep, and REM sleep), sleep timing (bedtime, sleep onset, awakenings, final wake time), and sleep continuity indices (wake after sleep onset and sleep efficiency). Secondary analyses will include signal-level EEG features such as spectral power in conventional frequency bands and spindle-like activity. Higher sleep efficiency and higher proportions of deep (slow-wave) sleep will be interpreted as better sleep quality. |
Baseline (3 consecutive nights within 2 weeks before treatment), post-treatment (3 consecutive nights within 21±7 days after last HBOT/Sham session), and at the end of the 3-month follow-up period (3 consecutive nights)
|
|
Orthostatic Intolerance - 10-min NASA Lean Test (NLT)
時間枠:Baseline, monthly during treatment (3 months), at the post-treatment evaluation (within 21±7 days after last HBOT/Sham session), monthly during follow-up (3 months), at the end of the follow-up period (end of study evaluation).
|
The 10-min NASA Lean Test (NLT) will be performed by asking the subject to lay supine for 10 min and then leaning against a wall for 10 min, while blood pressure and heart rate are measured
|
Baseline, monthly during treatment (3 months), at the post-treatment evaluation (within 21±7 days after last HBOT/Sham session), monthly during follow-up (3 months), at the end of the follow-up period (end of study evaluation).
|
|
Body Composition
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Body composition will be assessed using the seca mBCA Ultra, a clinically validated segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) system. The device estimates fat mass, fat-free mass, skeletal muscle mass, and total body water based on multi-frequency impedance measurements across body segments. Outcomes will include absolute values (kg or liters) and relative values (percentage of body weight) for each compartment. Higher fat mass and body fat percentage indicate greater adiposity, whereas higher fat-free mass and skeletal muscle mass indicate greater lean tissue. |
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Hand Grip test
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Quick, non invasive assessment of the maximal force generated when squeezing a hand dynamometer.
Reflecting strength of the hand and forearm muscles and serving as a proxy for overall muscle weakness, fatigability, and disease severity
|
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Peripheral blood biomarkers
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Whole blood and plasma will be collected and stored for future biomarker analysis
|
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
|
Muscle biopsy
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session.
|
A voluntary test.
Participants will undergo a muscle biopsy using a 0.3mm Trucut needle in an aseptic technique.
Muscle sample will be analysed using the Oxygraph (Oroboros Inc, Austria) for oxygen respiratory function, as well as staining for mitochondrial proteins and Mitochondrial DNA.
|
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session.
|
|
FUNCAP55 - a 55-item functional capacity questionnaire
時間枠:The day after each CPET. and once a month during the study
|
Reliable for assessing functional capacity.
May assist in diagnosis and follow-up.
|
The day after each CPET. and once a month during the study
|
|
Urine Test
時間枠:Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
Taken and stored for future analysis.
|
Baseline, post treatment evaluation within 21±7 days of last HBOT/Sham session, End of study evaluation: at the end of 3 month follow-up period
|
協力者と研究者
捜査官
- 主任研究者:Eli Kravchik, MD、principle investigator
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。